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journal homepage: www.elsevier .com/locate/ ih jLetter to the EditorCardiology blooms at ACC 2014 at Washington DC
but no cherry blossomsThe 65th annual meeting of the American College of Car-
diologywas held fromMarch, 29th to 31st, 2014 inWashington
DC, and attracted more than 20,000 participants from around
the world, including clinicians, academicians, allied health
professionals, and others interested in cardiology. The con-
ference highlighted recent advances in the treatment, man-
agement, and prevention of cardiovascular diseases. There
were joint sessions featuring more than 35 partner societies
and organizations. We happened to be there as Cardiological
Society of India representatives and participated in joint ses-
sions with ACC & Inter American society of Cardiology. Our
President Dr. Venugopal took part in the Symposium, which
focussed on Conquering Healthcare Challenges.
ACC President John Harold welcomed a full house to the
65th anniversary meeting and it was interesting to know that
ACC was coming to Washington for the first time despite it
being the ACC headquarters. Following the tributes, National
Heart, Lung and Blood Institute Director Gary Gibbons kicked
off the sessions with the Simon Dack lecture, the annual
tradition of honoring the legacy of one of the ACC founders.
Gibbons said that the field of cardiology couldn’t be more dy-
namic and poised to help with this transformation (of turning
discovery science to health of the nation). The showcase ses-
sion closed with a special presentation of the second ever
CardioSmart Patient Advocate Award to famed comedian
Dana Carvey. No stranger to heart disease - undergoing four
angioplasties and a double Bypass himself, Carvey has been
able to leverage his fame and unprecedented comic ability to
reach millions of people about the importance of early detec-
tion and heart disease prevention.
ACC 2014 offered seven key note lectures featuring
speakers whose outstanding contributions to the field of
Cardiovascular medicine have made them venerated in the
eyes of their peers and that included Eugene Braunwald, A.
John Camm, Murray Essler, Jessica L. Mega, Roberta G.
Williams, Pradiman Shaw and others. It is interesting to know
that ACC14 offered us 400 h of Presentation.
With more than 1000 Fellows in Training (FIT) and Early
career Professional members (ECP) participating in ACC14,
this year’s meeting offered unprecedented opportunities for
the next generation of cardiovascular specialists to network
and gain hands-on training through special targeted pro-
gramming which included addressing scholarship andeducation, broad careers in cardiology and mentoring
opportunities.
Sorting out Risk prevention in 2014, a day long educational
offering - unlike anything ever experienced at the Annual
scientific session e saw the experts discussing the best
emerging science in prevention. Throughout the conference
stimulating discussions were taking place on emerging ther-
apies for management of atherosclerosis, statin therapy and
lipid management in real world, pharmacotherapy and other
issues in decreasing cardiovascular risk in diabetes, resistant
hypertension, personalized medicine andmany others. There
were also Women’s sessions to provide new Gender specific
care. ACC recently launched its own CVD in Women Com-
mittee, which aim to foster the development of specific
investigation where sex specific differences exist or are
suspected.
Late Breaking Trials session in the Main arena are the
highlights of any ACC. This time nineteen late breaking trials
were discussed in four sessions over the three days of the
conference. Possibly the best amongst them were Simplicity
HTN 3,Madit CRT LTFU, Heat PPCI, CoreValveUS Pilot trial and
Laplace 2, not to speak of the other Negative trials like Stability
and Alecardio. In the SYMPLICITY HTN-3 trial, Deepak L.
Bhatt, M.D., of Harvard Medical School in Boston, and col-
leagues found that renal denervation failed to significantly
decrease systolic blood pressure from baseline in six months
as well as average 24-h levels by ambulatory blood pressure
monitoring. The investigators randomized 535 patients with
resistant hypertension and systolic blood pressure of 160 mm
Hg or higher to renal denervation. The first blinded random-
ized controlled trial on RDN failed to meet its efficacy end
points and does that mean it is the “end of the road for renal
denervation”. The Global Registry data on RDN presented by
Michael Bohm on the next day of Late breaking trial session
made us believe that the debate will continue till we settle the
issue with a large RCT. In the Madit CRT LTFU trial, Ilan
Goldberg concluded that in patients with mild heart failure
symptoms, left ventricular dysfunction and LBBB, early
intervention with CRT is associated with a significant long
term survival benefit. The HEAT PPCI trial from Liverpool
Heart and Chest hospital generated a lot of heat and dust.
Gregg stone who chaired the session - he was the PI of the
HORIZON AMI study - obviously didn’t like the conclusion
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 2 5 3e2 5 4254which reads as Bivalurudin and Heparin gave similar impact
on MACE events, similar GPI use with both having similar
bleeding rates. In the CoreValve U.S. Pivotal High Risk Trial,
David H. Adams, M.D., of the Mount Sinai Medical Center in
New York City, and colleagues found that survival at one year
was superior in patients undergoing a transcatheter aortic
valve replacement (TAVR) with the CoreValve as compared to
surgery. The study randomized 795 patients with severe
symptomatic aortic stenosis with increased risks for open
heart surgery to TAVR with a CoreValve or surgical valve
replacement. Laplace 2 showed that the PCS K9 monoclonal
antibody inhibitor evolocumab significantly reduces low-
density lipoprotein (LDL) cholesterol. One can go on discus-
sing the other trials but then every bit of information is
available at Cardiosource (if you are a subscriber) or at Clinical
Trial Results.org (Free).
Medical knowledge doubles every three to five years. And
so to the extent that that’s true, one would need to have .
personalized programmes, journal reading, coming to na-
tional meetings, getting onlinedyou’d have to have some
method of being up to date. The ACC helps its members in
MOC (maintenance of Certification programme) so as to
advance cardiologists’ knowledge, skills and attitude and in
turn promote high value healthcare and the triple aim of
better care, better health and less cost. We in India haveshown the world that we can provide quality cardiac care at
affordable costs and possibly what is lacking is the recertifi-
cation, which should be done appropriately.
Washington DC is a visitors paradise with a profusion of
national monuments and memorials, museums and per-
forming arts .The National cherry blossom festival which
starts from the third Saturday ofMarch attracts 700,000 people
each year and it was something we thought of enjoying apart
from the brainstorming scientific sessions. Alas, the unkind
weather - it rained on almost all days of ACC and robbed from
us the pleasant sights, except on the last day. We couldn’t
enjoy the Cherry blossoms but then Cardiology blossomed full
during ACC 2014.
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